The global dog vaccine market size is anticipated to reach USD 2.6 billion by 2030 and display a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to the increasing trend of pet humanization, pet ownership among millennials, and rising consciousness regarding preventive healthcare. According to Boehringer Ingelheim International GmbH, 35% of millennials and 32% of baby boomers own a pet. In addition, the rise in pet spending and insurance is also expected to add to the growth of this market. According to an article published by WorldAnimalFoundation.org in February 2023, dog owners spent approximately USD 570 more than cat owners.
Moreover, the increasing pet population, rising income levels in emerging markets of Asia-Pacific, such as China and India, and consequent changes in the lifestyle of people are expected to impact the growth of the dog vaccine industry significantly. For instance, according to an article published by the Economic Times in July 2023, the per capita income in India is expected to increase by 1.6 times to reach USD 4000 by 2030.
Request a free sample copy or view report summary: Dog Vaccine Market Report
Based on vaccine type, the modified/attenuated live vaccine segment accounted for the largest revenue share of 52.4% in 2022, as they help prevent disease and provide long-term immunity
Based on disease type, the canine rabies segment is expected to grow at the fastest CAGR of 6.9% over the forecast period due to the high prevalence of this disease and its zoonotic potential
Based on route of administration, the injectable segment accounted for the largest revenue share of 76.1% in 2022, owing to their convenience and ability to administer accurate dosage amounts
Based on duration of immunity, the 1-year segment dominated the market with a share of 51.2% in 2022 owing to their convenience
Based on component, the combined vaccines segment accounted for the largest market share of 65.5%. It is expected to grow at the fastest CAGR of 6.2% over the forecast period due to its ability to protect against more than one disease
North America dominated with a share of 38.8% in 2022, owing to the presence of major players and increasing awareness regarding preventive healthcare for pets. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR of 7.0% over the forecast period due to untapped opportunities in the emerging economies of China and India
Grand View Research has segmented the global dog vaccine market based on vaccine type, disease type, route of administration, duration of immunity, component, and region:
Dog Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)
Modified/ Attenuated Live
Dog Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
Canine Infectious Respiratory Disease Complex (CIRDC)
Canine Parvovirosis/ Parvovirus Disease
Canine Lyme Disease
Infectious Canine Hepatitis
Dog Vaccine Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Dog Vaccine Duration of Immunity Outlook (Revenue, USD Million, 2018 - 2030)
Dog Vaccine Component Outlook (Revenue, USD Million, 2018 - 2030)
Dog Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
List of Key Players in the Dog Vaccine Market
Hester Biosciences Limited
Boehringer Ingelheim International GmbH
Brilliant Bio Pharma
Merck & Co., Inc.
Zoetis Services LLC.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."